Quantcast
Home > Quotes > IMMU
IMMU

Immunomedics, Inc. Common Stock (IMMU) Quote & Summary Data

$18.25
*  
0.57
3.03%
Get IMMU Alerts
*Delayed - data as of Nov. 14, 2018 15:00 ET  -  Find a broker to begin trading IMMU now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    IMMU Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 18.24 / $ 18.27
Today's High / Low
$ 19.21 / $ 17.26
Share Volume
2,659,017
50 Day Avg. Daily Volume
1,836,196
Previous Close
$ 18.82
52 Week High / Low
$ 27.33 / $ 8.68
Market Cap
3,467,854,689
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
2,659,017
50 Day Avg. Daily Volume:
1,836,196

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.25

Trading Range

The current last sale of $18.25 is 110.25% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 19.21 $ 27.33
 Low: $ 17.26 $ 8.68

ETFs with IMMU as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
271% ALPS Medical Breakthroughs ETF (SBIO) -6.28 (-16.18%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer. Our advanced proprietary technologies allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with chemotherapeutics, cytokines or toxins. Our most advanced product candidate is sacituzumab govitecan ("IMMU-132"), an antibody-drug conjugate ("ADC") that has received Breakthrough Therapy Designation ("BTD") from the United States Food and Drug Administration (the "FDA") for the treatment of patients with metastatic triple-negative breast cancer ("mTNBC") who previously received at least two prior therapies for metastatic disease. Our current focus is to commercialize sacituzumab govitecan as a third-line therapy for patients with mTNBC in the United States.  ... More ...  


Risk Grade

Where does IMMU fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 19
Open Date:
Nov. 14, 2018
Close Price:
$ 18.82
Close Date:
Nov. 13, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x